

## Pexiganan

<b>Cat. No.:</b>	HY-105088	
<b>CAS No.:</b>	147664-63-9	
<b>Molecular Formula:</b>	C <sub>122</sub> H <sub>210</sub> N <sub>32</sub> O <sub>22</sub>	
<b>Molecular Weight:</b>	2477.17	GIGKFLKKAKKFGKAFVKILKK-NH <sub>2</sub>
<b>Sequence Shortening:</b>	GIGKFLKKAKKFGKAFVKILKK-NH2	
<b>Target:</b>	Bacterial	
<b>Pathway:</b>	Anti-infection	
<b>Storage:</b>	Sealed storage, away from moisture	
	Powder -80°C 2 years	
	-20°C 1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 100 mg/mL (40.37 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
	1 mM		0.4037 mL	2.0184 mL	4.0369 mL
	5 mM		0.0807 mL	0.4037 mL	0.8074 mL
	10 mM		0.0404 mL	0.2018 mL	0.4037 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Pexiganan (MSI 78 free base) is a synthetic analog of magainin 2. Pexiganan is a potent and orally active broad-spectrum antimicrobial peptide. Pexiganan can be used in the research of infections, such as diabetic foot ulcer infections<sup>[1]</sup>.

#### In Vitro

Pexiganan (MIC: 0-128 µg/mL approximately) shows broad-spectrum antibacterial activity against 3,109 clinical isolates of gram-positive and gram-negative, anaerobic and aerobic bacteria<sup>[2]</sup>.  
 Pexiganan (4 µg/mL) inhibits gastric ulcer strain and gastric cancer strain<sup>[3]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Pexiganan (1, 3, 10 or 30 mg/kg, p.o., daily for three consecutive days) shows H. pylori clearance efficiency in H. pylori-infected mouse<sup>[3]</sup>.  
 Pexiganan (1 mg/kg, i.p.) shows antimicrobial activity in rat models of Gram-negative septic shock<sup>[4]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	H. pylori-infected mouse <sup>[3]</sup> .
Dosage:	1, 3, 10 or 30 mg/kg
Administration:	Oral administration, daily for three consecutive days.
Result:	Lowered H. pylori urease activities in mouse stomachs.
Animal Model:	Rat models of Gram-negative septic shock (induced by E.coli ATCC 25922) <sup>[4]</sup> .
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Displayed antimicrobial activities and survival rates of 67.7%.

## REFERENCES

- [1]. Lamb HM, et al. Pexiganan acetate. *Drugs*. 1998 Dec;56(6):1047-52; discussion 1053-4.
- [2]. Ge Y, et al. In vitro antibacterial properties of pexiganan, an analog of magainin. *Antimicrob Agents Chemother*. 1999 Apr;43(4):782-8.
- [3]. Zhang XL, et al. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo. *Molecules*. 2015 Mar 2;20(3):3972-85.
- [4]. Giacometti A, et al. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. *Peptides*. 2005 Feb;26(2):207-16.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA